Back To: Home : Featured Technology : Liquid Biopsy

CLICK HERE FOR WHAT'S NEW IN:
 

Companies ink cancer MDx agreement
February 2014
by  |  Email the author
EDIT CONNECT

SHARING OPTIONS:

SAN FRANCISCO—CollabRx Inc. and Cynvenio Biosystems Inc. have begun a multiyear agreement to utilize CollabRx technology and content resources to support the clinical interpretation of genetic sequencing-based tests by Cynvenio. Per the terms of the agreement, several CollabRx products, including the Genetic Variant Annotation (GVA) Service, will be paired with tumor mutation profiling performed by Cynvenio. Reports generated with the GVA Service will be offered with Cynvenio’s ClearID Breast Cancer blood test, and Cynvenio will combine the test results with clinically actionable data provided by the GVA Service. Thomas Mika, chairman, president and CEO of CollabRx, noted that, “We chose to extend CollabRx expertise and services to ‘liquid biopsy’ for the first time with Cynvenio because they are at the forefront of the sector with a strong focus on advancing personalized medicine in cancer.”
 
Code:

Back


PAGE UTILITIES


CONTACT US
DDNEWS
Published by Old River Publications LLC
19035 Old Detroit Road
Rocky River, OH USA 44116
Ph: 440-331-6600  |  Fax: 440-331-7563
 
© Copyright 2017 Old River Publications LLC. All righs reserved.  |  Web site managed and designed by OffWhite.